T1	intervention 48 57	Tamoxifen
T2	condition 69 139	Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
T4	control 653 660	placebo
T3	duration 168 175	5 years
T5	eligibility 703 854	women with hormone-sensitive or unknown breast intraepithelial neoplasia, including atypical ductal hyperplasia and lobular or ductal carcinoma in situ
T6	outcome-Measure 886 949	incidence of invasive breast cancer or ductal carcinoma in situ
T7	No-of-participants 951 963	Five hundred
T8	average-age 970 996	75 years of age or younger
T9	outcome 1102 1119	neoplastic events
T10	intervention-value 1099 1101	14
T11	control-value 1139 1141	28
T12	outcome 1340 1367	contralateral breast events
T13	intervention-value 1376 1381	three
T14	control-value 1384 1386	12
T15	intervention-value 1371 1374	75%
T16	outcome 1447 1472	Patient-reported outcomes
T17	outcome 1608 1630	serious adverse events
T18	intervention-value 1605 1607	12
T19	control-value 1650 1652	16
T20	adverse-effect 1681 1701	deep vein thrombosis
T21	adverse-effect 1710 1736	stage I endometrial cancer
T22	intervention-value 1677 1680	one
T23	intervention-value 1706 1709	one
T24	adverse-effect 1760 1778	pulmonary embolism
T25	control-value 1756 1759	one
